Description : Co-administration of pitavastatin and fenofibrate should be considered as one of the options for the treatment of hypercholestrolemic patients with hupertriglyceridemia, in whom, control of the lipid profile sometimes becomes problematic in routine clinical practice - Japanese Clincal Medicine 2011:2 57-66
Pitvastatin and atorvastatin cuased significant and almost comparable reductions in serum levels of total cholesterol (-35.4 vs -33.8%), low-density lipoprotein cholesterol (-42.8 vs.-40.7%), and triglyceride (-26.1 vs -29.4%) and significantly increased serum levels of high-density lipoprotein cholesterol (12.1 vs 11.4%). Under these conditions, plasma levels of CoQ10 were reduced by atorvastatin (-26.1%, P=0.0007) but not by pitavastatin (-7.7%, P=0.39) - Clin Pharmacol Ther, 2008 May;83(5):731-9
Description : Ezetimibe plus statin therapy in ACS patients with dyslipidemia decreased LDL-C and sitosterol levels more than statin therapy solo. Sitosterol Elevation was predictor of poor response to aggressive lipid lowering treatment in ACS patients - journal of Lipids Volume 2015
Study demonstrated for the first time that co-administration of ezetimibe 10mg enhanced proteinuria-lowering effects of pitavastatin 2mg. in non-diabetic CKD patients partly via a cholesterol-independent manner, Ezetimibe may have pleiotropic actions that could contribute to reno-protective properties of this lipid-lowering agent - Clinical Pharmacokinetics, May 2005, Volume 44, Issue 5, pp 467-494
